Details for Patent: 8,263,647
✉ Email this page to a colleague
Title: | Treatment of sleep disturbances |
Abstract: | The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients. |
Inventor(s): | Cook; Graham D. (Midlothian, VA), Koch; Todd S. (Powhatan, VA), Giamalva; David H. (Gleen Allen, VA), Bianco; Justin (Vineland, VA), Fort; James J. (Midlothian, VA), Doyle; Geraldine (Chatham, NJ), Cooper; Steven (Denville, NJ) |
Assignee: | Wyeth LLC (Madison, NJ) |
Filing Date: | Apr 10, 2008 |
Application Number: | 12/082,342 |
Claims: | 1. A solid dosage form comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance, wherein the solid dosage form has a bilayer configuration having a first layer and a second layer, wherein the first layer comprises all of the ibuprofen in an amount from 50 mg to 800 mg and the second layer comprises the diphenhydramine or a salt thereof in an amount from 12.5 mg to 50 mg. 2. The composition of claim 1, wherein the ibuprofen is present in an amount of 200 mg. 3. The composition of claim 1, wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate. 4. The composition of claim 3, wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate. 5. The composition of claim 4, wherein the diphenhydramine HCl is present in an amount of 25 mg. 6. The composition of claim 4, wherein the diphenhydramine citrate is present in an amount from 19 mg to 38 mg. 7. The composition of claim 6 wherein the diphenhydramine citrate is present in an amount of 38 mg. 8. The composition of claim 7, wherein the sleep disturbance affects sleep duration. 9. A composition to treat a pain-associated sleep disturbance comprising a liquid composition formulated inside a soft gelatin capsule, wherein said liquid composition consisting of about 200 to about 400 mg of ibuprofen and between about 10 to about 50 mg of diphenhydramine, and a solubilizing agent consisting of polyethylene glycol to prevent negative interactions between the ibuprofen and the diphenhydramine. 10. The composition of claim 9, wherein the ibuprofen is present in an amount of 200 mg. 11. The composition of claim 10, wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate. 12. The composition of claim 11, wherein the diphenhydramine is present as diphenhydramine HCl or diphenhydramine citrate. 13. The composition of claim 12, wherein the diphenhydramine HCl is present in an amount from 12.5 mg to 50 mg. 14. The composition of claim 13, wherein the diphenhydramine HCl is present in an amount of 25 mg. 15. The composition of, claim 11 wherein the diphenhydramine citrate is present in amount from 19 mg to 38 mg. 16. The composition of claim 15, wherein the diphenhydramine citrate is present in an amount of 38 mg. 17. The composition of claim 9, wherein the sleep disturbance affects sleep duration. 18. A solid dosage form comprising ibuprofen and diphenhydramine in amounts effective to treat a pain-associated sleep disturbance, wherein the solid dosage form has a configuration having a first layer and a second layer, wherein the first layer comprises all of the ibuprofen and the second layer comprises the diphenhydramine or a salt thereof, thereby minimizing the negative interaction between the diphenhydramine and the ibuprofen, wherein the solid dosage form further comprises at least one of calcium stearate, croscarmellose sodium, glyceryl behenate, lactose, microcrystalline cellulose, silicon dioxide colloidal, sodium lauryl sulfate, sodium starch glycolate, corn starch, preglatinized starch, starch or stearic acid. |